You are here

FDA Approves Extended-Release Levomilnacipran (Fetzima) for Treatment of Major Depressive Disorder

Depression and disability scales significantly improved versus placebo (July 26)

The FDA has give the green light to levomilnacipran extended-release capsules (Fetzima, Forest Laboratories/ Pierre Fabre Laboratories), a once-daily serotonin and norepinephrine reuptake inhibitor (SNRI), for the treatment of major depressive disorder (MDD) in adults.

The efficacy of extended-release levomilnacipran versus placebo was demonstrated in three pivotal, double-blind phase III trials. More than 1,600 adults with MDD received a once-daily dose of either levomilnacipran (40, 80, or 120 mg) or placebo in the three trials. In each study, the primary endpoint was the change from baseline to endpoint in the Montgomery–Åsberg Depression Rating Scale (MADRS) total score, and the secondary endpoint was the change from baseline to endpoint in the Sheehan Disability Scale (SDS) total score.

In all three studies, statistically significant improvements were observed in the levomilnacipran groups compared with the placebo groups on both the primary and secondary endpoints.

The most common adverse reactions were nausea, constipation, hyperhidrosis, increased heart rate, erectile dysfunction, tachycardia, vomiting, and palpitations. Rates of adverse events were generally consistent across doses (40–120 mg); the only dose-related adverse events were urinary hesitation and erectile dysfunction.

MDD affects approximately 16 million adults in the U.S. every year. The World Health Organization (WHO) predicts that depression will become the second leading cause of disability by the year 2020.

Source: Forest Laboratories; July 26, 2013.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
National Statistics Report Factors In Race, Ethnicity for the First Time